CMTM6, a potential immunotherapy target

  title={CMTM6, a potential immunotherapy target},
  author={Jie Liang and Shaohua Li and Wei Li and Wei Rao and Shuo Xu and Haining Meng and Feng-Hua Zhu and Dongchang Zhai and Mengli Cui and Dan Xu and Jinzhen Cai and Bei Zhang},
  journal={Journal of Cancer Research and Clinical Oncology},
The CKLF-like MARVEL transmembrane domain-containing protein 6 (CMTM6), which binds to the programmed death ligand 1 (PD-L1) and stabilizes the expression of PD-L1 on the cell surface, has been recently discovered as a novel regulator of PD-L1 expression in cancer. PD-L1 is an immune checkpoint inhibitory molecule that can mediate the immune escape of tumor cells in various tumors and has been studied intensively in recent years. In 2017, two articles simultaneously reported that CMTM6 can… 

Figures and Tables from this paper


The role of exosomal PD-L1 in tumor progression and immunotherapy
The role of exosomes in the regulation of tumor progression and the potential resistance mechanism to immunotherapy via exosomal PD-L1 are discussed and it is proposed that exosome PD- L1 may have the potential to be a target to overcome resistance to anti-PD-1/PD-L 1 antibody therapy.
Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and association with outcome on immunotherapy
High CMTM6 and PD-L1 co-expression in the stromal compartment was significantly associated with longer survival in treated patients and shows potential as a predictive factor for ICI treatments.
Novel regulators of PD-L1 expression in cancer: CMTM6 and CMTM4-a new avenue to enhance the therapeutic benefits of immune checkpoint inhibitors.
Recently discovered immune checkpoint pathways, including programmed death receptor 1/programmed death ligand 1 (PD-1/PD-L1) signaling pathway, were shown to protect host from overactive T-effector cells not only in cancer but also during microbial infections.
CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
Insight is provided into the biology of PD-L1 regulation, a previously unrecognized master regulator of this critical immune checkpoint is identified, and a potential therapeutic target to overcome immune evasion by tumour cells is highlighted.
Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
The data reveal that PD-L1 relies on CMTM6/4 to efficiently carry out its inhibitory function, and suggest potential new avenues to block this pathway.
CMTM6 stabilizes PD-L1 expression and refines its prognostic value in tumors.
The PD-1 protein turned out to be a receptor delivering a co-inhibitory signal, playing a decisive role in maintaining peripheral tolerance and impeding autoimmunity, but with no effect on cell apoptosis.
CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer
The coexpression status of CMTM6 and PD-L1 can be used as a new classification to stratify the risk of progression and death for patients with CRC, especially for patients receiving adjuvant chemotherapy.
Exosomal PD-L1 Contributes to Immunosuppression and is Associated with anti-PD-1 Response
It is reported that metastatic melanomas release extracellular vesicles, mostly in the form of exosomes, that carry PD-L1 on their surface, suggesting a mechanism by which tumours could evade the immunesystem, and the potential application ofExosomal PD- L1 to monitor patient responses to checkpoint therapies.
CMTM6 Stabilizes PD‐L1 Expression and Is a New Prognostic Impact Factor in Hepatocellular Carcinoma
A large cohort study found that CMTM6 co‐expressed with PD‐L1 was strongly associated with the clinical outcome in patients with HCC, and might be useful for patient selection in immune checkpoint therapy.